The National Institute on Aging and the Alzheimer's Association convened three separate work groups in 2011 and single work groups in 2012 and 2018 to create recommendations for the diagnosis and characterization of Alzheimer's disease (AD). Later-changing Core 2 biomarkers (biofluid and tau PET) can provide prognostic information, and when abnormal, will increase confidence that AD is contributing to symptoms.
Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.
Read the full paper
Access the original peer-reviewed research via OpenAlex.
| Category | 🧬 Medicine & Biology |
| Published | Jun 27, 2024 |
| Journal | Alzheimer s & Dementia |
| Authors | Clifford R. Jack, J. Scott Andrews, Thomas G. Beach, Teresa Buracchio, Billy Dunn |
| DOI | 10.1002/alz.13859 |
| Citations | 2,175 |
| Source | OpenAlex |